目的 系統(tǒng)評價(jià)貞芪扶正制劑輔助化療治療腫瘤的療效與安全性，為臨床治療提供循證參考。方法 計(jì)算機(jī)檢索中文數(shù)據(jù)庫中文學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）、萬方數(shù)據(jù)庫（WanFang Data）、維普中文期刊全文數(shù)據(jù)庫（VIP）、PubMed、Cochrane圖書館有關(guān)貞芪扶正制劑輔助化療治療腫瘤的隨機(jī)對照試驗(yàn)（RCT），檢索時(shí)限為各數(shù)據(jù)庫建庫起至2021年3月。以Cochrane 5.3偏倚風(fēng)險(xiǎn)評估工具評價(jià)納入文獻(xiàn)質(zhì)量，采用RevMan 5.3統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果 共納入33項(xiàng)RCTs，包括2 666例患者。Meta分析結(jié)果顯示，貞芪扶正制劑輔助化療治療腫瘤能顯著提高臨床有效率［RR＝1.34，95% CI=（1.21，1.45），P<0.000 01］，同時(shí)還能改善患者生存質(zhì)量［RR＝2.24，95% CI=（1.56，3.20），P<0.000 1］，提高患者免疫力，改善造血功能抑制，降低肝腎毒性等發(fā)生率，與對照組比較差異均有統(tǒng)計(jì)學(xué)意義。結(jié)論 貞芪扶正制劑輔助化療治療腫瘤的療效與安全性均較好。

Objective To systematically review the efficacy and safety of Zhenqifuzheng preparation combined with chemotherapy in the treatment of cancer,and provide evidence-based reference for clinical treatment. Methods Computer searches of CNKI, CBM, WanFang, VIP, PubMed, and Cochrane Library were conducted to collect randomized controlled trials (RCTS) on ZhenqiFuzheng preparation combined with chemotherapy in the treatment of cancer, from the time of establishing database to May 2021. Quality evaluation was conducted by Cochrane 5.3 bias risk assessment tool, and Meta-analysis was conducted by RevMan 5.3 statistical software. Results A total of 33 RCTs were enrolled, including 2 666 patients. The results of Meta-analysis showed that Zhenqifuzheng preparation combined with chemotherapy in the treatment of tumor can significantly improve the effective rate [RR ＝ 1.34, 95%CI = (1.21, 1.45), P < 0.000 01], but also can improve the quality of life [RR ＝ 2.24, 95%CI = (1.56, 3.20), P < 0.000 1], enhance immunity, improve hematopoietic function inhibition, reduce the incidence of hepatorenal toxicity, the differences were statistically significant. Conclusion Zhenqifuzheng preparation combined with chemotherapy has good efficacy and safety in the treatment of cancer.

R286.91

西安交通大學(xué)第一附屬醫(yī)院科研發(fā)展基金資助項(xiàng)目（2020ZYTS-17）